Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic siRNA: state of the art
Bo Hu, Liping Zhong, Yuhua Weng, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1089

Showing 1-25 of 1089 citing articles:

The growth of siRNA-based therapeutics: Updated clinical studies
M. May Zhang, Raman Bahal, Theodore P. Rasmussen, et al.
Biochemical Pharmacology (2021) Vol. 189, pp. 114432-114432
Open Access | Times Cited: 378
Advances in targeted therapy for esophageal cancer
Yuan‐Han Yang, Lisa F. P. Ng, Wen Xu, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 370
Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines
Thai Thanh Hoang Thi, Estelle J. A. Suys, Jung Seok Lee, et al.
Vaccines (2021) Vol. 9, Iss. 4, pp. 359-359
Open Access | Times Cited: 362
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Rui Liu, Cong Luo, Zhiqing Pang, et al.
Chinese Chemical Letters (2022) Vol. 34, Iss. 2, pp. 107518-107518
Closed Access | Times Cited: 335
siRNA: Mechanism of action, challenges, and therapeutic approaches
Walhan Alshaer, Hadil Zureigat, Arwa Al Karaki, et al.
European Journal of Pharmacology (2021) Vol. 905, pp. 174178-174178
Closed Access | Times Cited: 279
Bioinspired exosome-like therapeutics and delivery nanoplatforms
Mei Lu, Yuanyu Huang
Biomaterials (2020) Vol. 242, pp. 119925-119925
Closed Access | Times Cited: 228
Therapeutic siRNA: State-of-the-Art and Future Perspectives
Maik Friedrich, Achim Aigner
BioDrugs (2022) Vol. 36, Iss. 5, pp. 549-571
Open Access | Times Cited: 220
Recent progress in non-native nucleic acid modifications
Luke K. McKenzie, Roberto El-Khoury, James D. Thorpe, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 8, pp. 5126-5164
Open Access | Times Cited: 219
Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 219
Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
Makhloufi Zoulikha, Qingqing Xiao, George Frimpong Boafo, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 2, pp. 600-620
Open Access | Times Cited: 178
Targeting iron metabolism in cancer therapy
Michael J. Morales, Xiang Xue
Theranostics (2021) Vol. 11, Iss. 17, pp. 8412-8429
Open Access | Times Cited: 157
Carbohydrate-based drugs launched during 2000−2021
Xin Cao, Xiaojing Du, Heng Jiao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 10, pp. 3783-3821
Open Access | Times Cited: 150
Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment
Shuai Guo, Kun Li, Bo Hu, et al.
Exploration (2021) Vol. 1, Iss. 1, pp. 35-49
Open Access | Times Cited: 141
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Sepideh Mirzaei, Mohammad Gholami, Kiavash Hushmandi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 137
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Sepideh Mirzaei, Mohammad Gholami, Farid Hashemi, et al.
Drug Discovery Today (2021) Vol. 27, Iss. 2, pp. 436-455
Open Access | Times Cited: 131
RNA modifications in physiology and disease: towards clinical applications
Sylvain Delaunay, Mark Helm, Michaela Frye
Nature Reviews Genetics (2023) Vol. 25, Iss. 2, pp. 104-122
Open Access | Times Cited: 117
RNA-targeting and gene editing therapies for transthyretin amyloidosis
Alberto Aimo, Vincenzo Castiglione, Claudio Rapezzi, et al.
Nature Reviews Cardiology (2022) Vol. 19, Iss. 10, pp. 655-667
Closed Access | Times Cited: 116
Insight Into the Prospects for RNAi Therapy of Cancer
Zhili Tian, Guohui Liang, Kunli Cui, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 111
The Current Status of Gene Therapy for the Treatment of Cancer
Tafere Mulaw Belete
Biologics (2021) Vol. Volume 15, pp. 67-77
Open Access | Times Cited: 109
Oligonucleotide Therapeutics: From Discovery and Development to Patentability
Lara Moumné, Anne-Céline Marie, Nicolas Crouvezier
Pharmaceutics (2022) Vol. 14, Iss. 2, pp. 260-260
Open Access | Times Cited: 103
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
Lulu Xue, Ningqiang Gong, Sarah J. Shepherd, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 22, pp. 9926-9937
Closed Access | Times Cited: 102
Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies
Wanqin Liu, Shanshan Liu, Ping Li, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4883-4883
Open Access | Times Cited: 85
Nucleic acid nanoassembly-enhanced RNA therapeutics and diagnosis
Mengnan Zhao, Rujing Wang, Kunmeng Yang, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 3, pp. 916-941
Open Access | Times Cited: 84
Where should siRNAs go: applicable organs for siRNA drugs
In–Sook Ahn, Chanhee S. Kang, Jinju Han
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 7, pp. 1283-1292
Open Access | Times Cited: 76
Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia
Bo Hu, Bo Li, Kun Li, et al.
Science Advances (2022) Vol. 8, Iss. 7
Open Access | Times Cited: 75
Page 1 - Next Page

Scroll to top